Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease

• DOI: 10.1093/intimm/dxaa022
• Publication Date: 2020-04-03T19:11:49Z
• Authors: Kunihiro Suzuki; Toyoshi Yanagihara; Koichiro Matsumoto; Hitoshi Kusaba; Takuji Yamauchi; Yuki Ikematsu; Kentaro Tanaka; Kohei Otsubo; Hiroyuki Inoue; Yasuto Yoneshima; Eiji Iwama; Masako Arimura-Omori; Eiji Harada; Naoki Hamada; Isamu Okamoto; Yoichi Nakanishi
• Keywords: Immune checkpoint

Immune-checkpoint inhibitors (ICIs) have improved clinical outcomes and are becoming a standard treatment for many cancer types. However, these drugs also induce immune-related adverse events, among which interstitial lung disease (ILD) is potentially fatal. The underlying mechanism of ILD induction by ICIs largely unknown. With the use flow cytometry, we determined expression levels immune-checkpoint proteins PD-1, TIM-3, TIGIT, LAG-3 PD-L1 in T cells bronchoalveolar lavage fluid (BALF) from patients with ICI-related compared them those sarcoidosis or related to connective tissue cytotoxic drug use. proportions CD8+ positive both PD-1 TIM-3 TIGIT BALF were significantly higher than other types ILD. A prominent increase proportion PD-1+PD-L1+ was apparent patient fatal case ILD, such positively correlated grade Our data reveal profiles may provide mechanistic insight into development this event.